PPARδ¹¹ PPARδ
Peroxisome Proliferator-Activated Receptor delta — a nuclear receptor that coordinates gene expression programs for fatty acid oxidation, mitochondrial biogenesis, and muscle fiber-type switching in skeletal muscle is encoded by the PPARD gene on chromosome 6. The rs1053049 variant sits in the 3' untranslated region (3'UTR) of exon 9 — a regulatory stretch of RNA that is not translated into protein but profoundly influences how much PPARD mRNA is produced, how long it persists in the cell, and ultimately how much PPARδ protein is available to drive its downstream program.

This SNP is the third of three tag variants in the PPARD gene that together define a haplotype with striking consequences for elite athletic potential. Alongside rs2267668 (5' region) and rs2016520 (5'UTR, +294T>C), rs1053049 completes the A/C/C haplotype that has been studied in competitive athletes across multiple cohorts. It was identified as an independently significant marker for elite athletic status in its own right, with additional effects on skeletal muscle insulin sensitivity and body composition response to exercise.

The Mechanism

The 3'UTR is a post-transcriptional control hub. Variants in this region can disrupt or create microRNA binding sites²² microRNA binding sites
MicroRNAs are short non-coding RNAs that bind to complementary sequences in the 3'UTR of target mRNAs, triggering degradation or translational repression. A single 3'UTR SNP can abolish or create such a binding site, altering the amount of protein produced from an unchanged coding sequence, alter mRNA secondary structure affecting transcript stability, or modify polyadenylation signals that control mRNA half-life. While the precise molecular mechanism for rs1053049 has not been elucidated by in vitro reporter assays at the same level of detail as the rs2016520 promoter variant, the pattern of phenotypic associations — particularly the contrast between TT and TC genotypes for skeletal muscle glucose uptake — is consistent with a functional effect on PPARD expression levels in muscle tissue.

The key distinction from rs2016520 is anatomical: the 5'UTR variant (rs2016520) primarily affects transcriptional initiation through Sp-1 binding, while a 3'UTR variant like rs1053049 is more likely to influence post-transcriptional stability or translation efficiency. These mechanisms can have tissue-specific effects, which helps explain why the two variants show partially overlapping but distinct associations across metabolic, athletic, and body composition phenotypes.

The Evidence

The foundational study on rs1053049's metabolic significance was conducted by Vänttinen et al. at the University of Turku³³ Vänttinen et al. at the University of Turku
Vänttinen M et al. Single nucleotide polymorphisms in the peroxisome proliferator–activated receptor δ gene are associated with skeletal muscle glucose uptake. Diabetes, 2005. In 129 healthy subjects who underwent euglycemic hyperinsulinemic clamp procedures with PET imaging, the TC genotype of rs1053049 was significantly associated with higher whole-body and skeletal muscle glucose uptake compared with TT homozygotes (P = 0.028). This was a direct measurement of in vivo insulin sensitivity at the tissue level, not an association with a proxy marker, and it established that rs1053049 independently modulates how efficiently skeletal muscle takes up glucose in response to insulin.

A lifestyle intervention study using whole-body MRI⁴⁴ lifestyle intervention study using whole-body MRI
Thamer C et al. Variations in PPARD determine the change in body composition during lifestyle intervention: a whole-body magnetic resonance study. J Clin Endocrinol Metab, 2008 found that PPARD rs1053049 (along with rs6902123 and rs2267668) significantly affected the magnitude of lifestyle-intervention-induced changes in adiposity, hepatic fat storage, and relative muscle mass. Carriers of the minor C allele showed less reduction in adipose tissue mass (both nonvisceral and visceral, P = 0.02 and P = 0.01 respectively) and hepatic lipids (P = 0.04) in response to a structured diet and exercise program. This finding provides a mechanistic basis for why PPARD variation contributes to individual differences in body composition response to training and identifies rs1053049 as a predictor of whether lifestyle intervention will yield the expected adipose tissue reduction.

The landmark haplotype analysis of 660 elite athletes⁵⁵ haplotype analysis of 660 elite athletes
Maciejewska-Karlowska A et al. Genomic haplotype within the Peroxisome Proliferator-Activated Receptor Delta (PPARD) gene is associated with elite athletic status. Scand J Med Sci Sports, 2014 demonstrated that rs1053049 was individually associated with overall elite athletic performance (P = 0.0002) and specifically with strength-endurance sport athletes (P = 0.0003) when comparing 660 elite Polish athletes to 704 healthy controls. Crucially, the haplotype analysis showed that the complete A/C/C haplotype across all three PPARD variants (rs2267668-A / rs2016520-C / rs1053049-C) was dramatically underrepresented in every subgroup of elite athletes compared with controls (P < 0.000001). This is one of the strongest haplotype associations ever reported in sports genomics, and it establishes that the C allele at rs1053049 — in haplotype context with the other two variants — is associated with lower elite athletic potential.

A 12-week training intervention in 168 Polish women⁶⁶ 12-week training intervention in 168 Polish women
Leońska-Duniec A et al. The polymorphisms of the PPARD gene modify post-training body mass and biochemical parameter changes in women. PLOS One, 2018 found that TT homozygotes at rs1053049 were overrepresented in the group with higher post-training triglyceride levels. Haplotype analysis revealed that the G/C/C haplotype (rs2267668-G / rs2016520-C / rs1053049-C) was associated with post-training increases in fat-free mass and lower levels of cholesterol and triglycerides — suggesting that the broader haplotype context around rs1053049 determines whether the C allele is favorable or unfavorable for a given metabolic phenotype.

A 2023 Chinese military exerciser study⁷⁷ 2023 Chinese military exerciser study
Correlation between PPARD rs2267668 and rs1053049 polymorphisms with lower-limb strength in Chinese male exercisers. Mil Med Sci, 2023 found that the TT genotype of rs1053049 was significantly more common in the strong lower-limb strength group than in the weak group (64.7% vs 44.6%, P = 0.011), and the T allele frequency was higher in stronger exercisers (81.6% vs 66.2%, P = 0.004), supporting the idea that the T allele at this 3'UTR site confers an advantage for lower-body power output in trained individuals.

Practical Actions

The metabolic picture at rs1053049 is nuanced. TT homozygotes show higher skeletal muscle glucose uptake efficiency in response to strength training and may have an advantage for lower-limb power development. However, TT carriers also tend to show higher post-training triglyceride levels in some aerobic training contexts, suggesting that dietary fat quality and omega-3 supplementation are particularly relevant for TT individuals.

TC carriers show the highest measured insulin sensitivity in skeletal muscle (Vänttinen 2005 euglycemic clamp data) and may represent an intermediate metabolic phenotype. CC homozygotes appear to have reduced response to lifestyle-intervention-induced fat loss and are part of the haplotype most underrepresented in elite athletes, suggesting that the double-C genotype confers less favorable body composition adaptations to training.

Regardless of genotype, omega-3 fatty acids (EPA and DHA) are natural PPARδ ligands that directly activate the receptor protein — nutritionally amplifying the same fat-oxidation and metabolic programs that this variant affects at the gene expression level.

Interactions

rs1053049 is one of three PPARD haplotype tag SNPs; the others are rs2267668 (5' region) and rs2016520 (5'UTR +294T>C, already profiled separately). The full haplotype (rs2267668/rs2016520/rs1053049) is more predictive of elite athletic potential than any individual SNP, with the A/C/C haplotype showing p < 0.000001 for underrepresentation in elite athletes. Understanding your genotype at all three sites provides the most complete picture of your PPARD haplotype and its implications.

PPARGC1A rs8192678 (Gly482Ser), encoding PGC-1alpha — the transcriptional coactivator that physically partners with PPARδ to drive mitochondrial biogenesis — interacts powerfully with the PPARD locus as a whole. PPARD CC at rs2016520 combined with PPARGC1A Gly/Gly yields OR 8.32 for elite endurance status; the rs1053049 genotype adds further context to where an individual falls within this receptor-coactivator interaction.

Adiponectin is the most abundant hormone secreted by fat tissue, yet its effects run counter to what you might expect: despite originating in adipose cells, it works against the pathological consequences of excess fat. It sensitizes muscle and liver to insulin, suppresses inflammatory cytokines, and protects blood vessel walls from the calcification that drives atherosclerosis. Circulating adiponectin levels vary 10-fold between individuals, and much of that variation is genetic. The rs1063537 variant (+3228 C/T) sits at position 186,856,286 on chromosome 3 within the 3' untranslated region (3'UTR) of ADIPOQ — a stretch of RNA sequence that, while not coding for protein, acts as a control panel for mRNA stability and translational efficiency¹¹ control panel for mRNA stability and translational efficiency
the 3'UTR contains binding sites for RNA-binding proteins and microRNAs that regulate how much mRNA is degraded versus translated into protein; small sequence changes here can shift the steady-state amount of adiponectin protein produced by adipocytes.

The Mechanism

The ADIPOQ gene lies on the plus strand of chromosome 3 and its 3'UTR is a regulatory hub. Adipocytes express multiple microRNAs²² microRNAs
small non-coding RNA molecules that bind to the 3'UTR of target mRNAs and typically reduce their translation or promote their degradation that target ADIPOQ mRNA, including miR-378 and miR-221. A C-to-T change at the +3228 position alters the local RNA secondary structure and microRNA binding affinity, modulating how quickly the transcript is cleared. The net result: C allele carriers have lower average circulating adiponectin than T allele carriers. In the Chingford cohort³³ In the Chingford cohort
Kyriakou et al. 2008, two female cohorts totalling >2,400 women, TT homozygotes had mean fasting adiponectin of 24.87 μg/mL versus 19.90 μg/mL in CC homozygotes — a 25% difference driven by a single nucleotide change in an untranslated region.

The C allele at rs1063537 is the GRCh38 reference allele and is far more common globally (~79% CC genotype, ~12% T allele frequency in Europeans, ~28% in East Asians). Because the common allele is the one that reduces adiponectin, the majority of the population operates at a mild adiponectin disadvantage relative to the rare T homozygotes.

The Evidence

Fasting adiponectin levels: The clearest functional signal for rs1063537 comes from Kyriakou et al. 2008⁴⁴ Kyriakou et al. 2008
Adiponectin gene ADIPOQ SNP associations with serum adiponectin in two female populations and effects of SNPs on promoter activity. J Hum Genet. 2008, which showed additive association (p=0.01) with serum adiponectin in 800 UK women, where each T allele added approximately 2–2.5 μg/mL to circulating levels. This replication in a second cohort of 1,629 women was not significant, suggesting a modest effect that requires large samples.

Type 2 diabetes: A Han Chinese case-control study of 768 subjects by Chung et al.⁵⁵ Chung et al.
Association of four insulin resistance genes with type 2 diabetes mellitus and hypertension in the Chinese Han population. Mol Biol Rep. 2014 found the T allele was protective against T2DM: allele frequency was 26.8% in T2DM cases versus 36.3% in controls (OR=0.64, 95% CI 0.45–0.91, p=0.014). This is consistent with the T allele's association with higher adiponectin, which enhances insulin sensitivity.

Coronary artery calcification: In the Multi-Ethnic Study of Atherosclerosis (MESA)⁶⁶ Multi-Ethnic Study of Atherosclerosis (MESA)
Associations of SNPs in ADIPOQ and subclinical cardiovascular disease. Atherosclerosis. 2012 — 712 African American participants — the AG/AA genotypes of rs1063537 (note: the study used a complementary notation for the same variant; the C allele corresponds to the major G in that encoding) were associated with a 35% greater coronary artery calcification (CAC) prevalence (PR=1.35–1.39, p=0.0005). This finding did not replicate in non-African ancestry groups, and rs1063537 was in high LD with the neighboring rs1063539 (r²=0.90 in African Americans), suggesting the signal may tag a haplotype specific to African ancestral populations.

Diabetic nephropathy: A Taiwanese longitudinal study by Lin et al. 2014⁷⁷ Lin et al. 2014
Adiponectin gene (ADIPOQ) polymorphisms correlate with the progression of nephropathy in Taiwanese male patients with type 2 diabetes. Diabetes Res Clin Pract. 2014 followed 566 T2DM patients with normoalbuminuria over six years. Males carrying the CC genotype had HR=1.89 for nephropathy progression (vs CT+TT, 95% CI 1.15–3.11, p=0.013). A more recent study of 538 Chinese Han T2DM patients found TT genotype carriers had a 2.47-fold higher risk of macroalbuminuria versus CC (p=0.016) — an apparently paradoxical finding that may reflect the nonlinear biology of adiponectin in established kidney disease, where adiponectin's anti-inflammatory signaling in the renal cortex may be altered by chronic inflammation.

Obstructive sleep apnea: Chen et al. 2019⁸⁸ Chen et al. 2019
ADIPOQ rs1063537 and obstructive sleep apnoea in Chinese Han adults. Targeted sequencing. OMICS. 2019 found CT/TT genotypes associated with 2.155-fold increased OSA risk (95% CI 1.149–4.041, p=0.017), with significantly higher apnea-hypopnea index (23.20 vs 17.15 events/hour, p=0.004). The mechanism may involve adiponectin's modulation of upper airway muscle tone and inflammation, though this finding requires replication.

Practical Implications

Low circulating adiponectin is a well-established driver of insulin resistance and cardiometabolic risk. For CC carriers, the primary levers are lifestyle factors known to upregulate ADIPOQ transcription and secretion: omega-3 fatty acids activate PPARγ⁹⁹ PPARγ
peroxisome proliferator-activated receptor gamma — the master regulator of adipocyte gene expression that directly drives ADIPOQ transcription, weight loss disproportionately raises adiponectin relative to other adipokines, and moderate caloric restriction upregulates adiponectin secretion. Monitoring fasting insulin and HOMA-IR provides a functional readout of whether adiponectin signaling is adequate.

For individuals with established T2DM, regular monitoring of urine albumin-to-creatinine ratio (uACR) is warranted given the nephropathy progression risk documented in this population — particularly in males, where the sex-specific HR=1.89 signal was found.

Interactions

rs1063537 lies at the 3' end of ADIPOQ within a block of variants that includes rs1063539 (high LD in African Americans, r²=0.90). The larger ADIPOQ haplotype context is defined by rs17300539 (−11391G>A promoter), rs182052 (−10066A>G intron), rs2241766 (+45T>G exon 2), and rs1501299 (+276G>T intron 2) — all already profiled in GeneOps. Together these variants define six common ADIPOQ haplotypes that explain substantially more variance in circulating adiponectin than any single SNP alone. Individuals carrying the CC genotype at rs1063537 plus the risk alleles at rs2241766 (G) and rs182052 (A) may face compounded reduction in adiponectin output via convergent transcriptional, post-transcriptional, and translational mechanisms.

Basonuclin-2 (BNC2) is a zinc finger transcription factor expressed during skeletal development with roles in regulating cell proliferation and differentiation in growth plate cartilage and intervertebral disc tissue. rs10738445 sits in intron 3 of BNC2¹¹ rs10738445 sits in intron 3 of BNC2
an intronic position at chr9:16,680,140 (GRCh38) within a transcriptional enhancer region, not in a protein-coding exon. Despite its non-coding location, this variant exerts a measurable functional effect on gene expression — and that shift in expression is what links it to adolescent idiopathic scoliosis²² adolescent idiopathic scoliosis
AIS — abnormal lateral curvature of the spine developing during the adolescent growth spurt, affecting approximately 2–3% of adolescents worldwide.

AIS is the most common pediatric spinal disorder. Most cases are mild, but roughly 10% of affected individuals develop curves severe enough to require bracing or surgery. The genetic architecture of AIS is complex and polygenic, with rs10738445 being one of the most consistently replicated susceptibility loci — validated across Japanese, Chinese, European, and multi-ethnic international cohorts.

The Mechanism

The C allele at rs10738445 creates an allele-specific transcription factor binding site³³ allele-specific transcription factor binding site
demonstrated by electrophoretic mobility shift assay (EMSA): the C allele binds the transcription factor YY1 approximately 1.3-fold more strongly than the A allele. YY1 (Yin Yang 1) is a ubiquitous zinc finger transcription factor that activates or represses genes depending on cellular context. At this locus, stronger YY1 binding drives higher BNC2 enhancer activity, elevating BNC2 mRNA levels in relevant tissues.

When BNC2 was overexpressed in zebrafish, the animals developed body curvature in a gene-dosage-dependent manner — direct experimental evidence that elevated BNC2 is sufficient to cause a scoliosis-like phenotype in a vertebrate model. In human AIS patients, BNC2 expression in spinal tissue is significantly higher than in controls, and expression magnitude correlates with curve severity (r=0.316, p=0.02), establishing a dose-response relationship between BNC2 expression and disease severity⁴⁴ establishing a dose-response relationship between BNC2 expression and disease severity
Xu et al. 2017, Chinese cohort of 2,645 patients and 2,746 controls.

The intersection with inflammatory pathways is less well characterised, but BNC2 expression is regulated by pro-inflammatory cytokines in growth plate and disc tissue. This may explain, in part, why AIS progression correlates with inflammatory markers and why this variant is catalogued in the innate immunity depth panel.

The Evidence

The discovery study by Ogura et al. 2015⁵⁵ Ogura et al. 2015
"A Functional SNP in BNC2 Is Associated with Adolescent Idiopathic Scoliosis", American Journal of Human Genetics, 2015 identified rs10738445 through GWAS followed by functional validation in 2,109 AIS cases and 11,140 controls from Japanese and Chinese populations. The C allele showed OR=1.21 (p=2.46×10⁻¹³) for AIS susceptibility. This was independently replicated in a Chinese cohort⁶⁶ a Chinese cohort
Xu et al., Molecular Genetics and Genomics, 2017 with 2,645 patients and 2,746 controls (OR=1.14–1.24), and confirmed in an international meta-analysis of 8,756 cases and 27,822 controls⁷⁷ international meta-analysis of 8,756 cases and 27,822 controls
Ogura et al., Scientific Reports, 2018 spanning seven ethnicities (using the linked proxy rs3904778, combined p=3.28×10⁻¹⁸, OR=1.19, 95% CI 1.14–1.24).

The most clinically actionable finding comes from Dai et al. 2025⁸⁸ Dai et al. 2025
"Genetic Variants Can Predict the Outcome of Brace Treatment in Patients With Adolescent Idiopathic Scoliosis", Spine, 2025. In 259 female AIS patients undergoing brace treatment, the C allele was the only significant predictor of treatment failure among five candidate SNPs tested (OR=1.59), with 30.5% of patients experiencing curve progression exceeding 5 degrees. This positions rs10738445 as a potential clinical decision-support marker for predicting which adolescents are likely to fail conservative bracing therapy.

Notably, the BNC2 locus association is specific to adolescent-onset disease: a Japanese cohort study⁹⁹ Japanese cohort study
Takeda et al. 2019 found no significant association with adult spinal deformity, indicating the variant operates through mechanisms tied to growth-phase skeletal development.

Practical Actions

For carriers of the C allele who are parents of adolescents, or who are in the adolescent growth phase themselves, the main implication is heightened awareness: AIS typically develops during the rapid growth spurt (ages 10–15 in girls, 12–16 in boys) and is most successfully treated when detected early. Screening by a paediatric orthopaedist during this window allows intervention before curves progress beyond the bracing threshold (Cobb angle 25–45°).

For adolescents already diagnosed with AIS and undergoing bracing, the Dai 2025 data suggest that C/C homozygotes face a meaningfully higher risk of brace failure (OR=1.59 per allele). This does not mean bracing should be abandoned — it remains first-line treatment — but it justifies closer radiographic monitoring intervals and earlier consideration of surgical consultation if curve progression occurs despite compliant brace use.

Interactions

rs10738445 lies approximately 1.8 kb from rs3904778, the proxy SNP used in most international GWAS and the meta-analysis by Ogura 2018. Both variants tag the same BNC2 locus; rs10738445 has been specifically validated as the functional variant through enhancer assay and YY1 binding experiments, while rs3904778 is the more widely studied GWAS tag. Carriers may have both SNPs genotyped — the two track closely but are not in perfect LD across all populations.

AIS susceptibility is polygenic. Other replicated loci include SOX9/KCNJ2 (rs12946942), TBX1 (rs1978060), and CHD7 (rs1017861). The Dai 2025 study examined these alongside rs10738445 and found only rs10738445 significantly predicted bracing outcome, suggesting it may capture a biologically distinct component of AIS pathogenesis related to the progression-relevant enhancer activity of BNC2.

Nucleobindin-2 (NUCB2) on chromosome 11p15.1 encodes the precursor protein for nesfatin-1¹¹ nesfatin-1
An 82-amino acid neuropeptide cleaved from NUCB2 that suppresses appetite and modulates insulin secretion via melanocortin MC3/MC4 receptors and CRF2 — functions leptin-independently, so it retains activity even in obesity where leptin resistance has developed, a neuropeptide governing appetite, glucose regulation, blood pressure, and sleep-wake cycling. The rs10766383 variant sits deep within an intron of NUCB2 (GRCh38 chr11:17308251), close to other studied NUCB2 intronic and coding variants — rs1330 and rs214101 — that have been linked to overlapping metabolic and oncological phenotypes. Like its neighbours, rs10766383 does not alter the nesfatin-1 amino acid sequence; its effects are thought to be regulatory, influencing NUCB2 transcript levels, splicing efficiency, or local chromatin accessibility.

The T allele is the minor allele globally (~25%) but reaches ~50% frequency in East Asian populations, explaining why its T2DM association was first detected in a Chinese Han cohort. The G allele is the GRCh38 reference and represents the common, wild-type NUCB2 expression state. This is a straightforward CLEAN pattern: GG carries the lowest genetic risk at this locus.

The Mechanism

As a deep intron variant, rs10766383 does not produce a protein-level change. Its regulatory mechanism is inferred from population-level associations and from what is known about how NUCB2 intronic variants affect gene expression. Possibilities include altered binding of transcription factors or RNA-binding proteins within an intronic regulatory element, changes in alternative splicing efficiency across NUCB2's multiple transcript isoforms, or effects on local histone modification patterns that alter promoter accessibility. Any of these would reduce the amount of NUCB2 protein available for proteolytic processing into nesfatin-1.

Reduced circulating nesfatin-1 is a consistent finding in obesity, insulin-resistant states, and several cancers — suggesting that an intronic variant that lowers NUCB2 expression could compound both metabolic and oncological vulnerability through a single mechanism of nesfatin-1 insufficiency. The sex-specific pattern of T2DM association (significant only in females in the Li 2020 cohort) mirrors the pattern seen at rs1330 in the same study and likely reflects estrogen-dependent modulation of NUCB2 transcription in hypothalamic and pancreatic circuits.

The Evidence

Type 2 diabetes. Li et al. (2020)²² Li et al. (2020)
Li XS et al. NUCB2 polymorphisms are associated with an increased risk for type 2 diabetes in the Chinese population. Endocr Connect, 2020 genotyped 578 T2DM patients against 1,609 healthy controls in a Chinese Han population. rs10766383 was one of four NUCB2 SNPs significantly associated with T2DM overall (T allele OR 1.29, 95% CI 1.12–1.47, P=0.0003). In sex-stratified analysis, the association was statistically significant only in females (OR 1.32, 95% CI 1.03–1.68, P=0.027) and did not reach significance in males (P=0.096). The T allele frequency in cases was 47.8% vs 41.6% in controls. No significant BMI association was detected at this specific locus, unlike rs1330 which did show BMI effects.

Oral cancer progression. Yu et al. (2026)³³ Yu et al. (2026)
Yu CC et al. Association of NUCB2 genetic variants with the clinicopathological features of oral cancer. 2026 examined four NUCB2 SNPs in 1,161 Taiwanese male oral cancer patients and 1,186 healthy controls. rs10766383 TG/GG genotypes (T as the analyzed allele here) were not associated with overall oral cancer susceptibility after lifestyle-factor adjustment. However, in patients aged ≥60 years, carrying TG or GG genotypes (at least one T allele) was associated with significantly higher risk of advanced-stage (III/IV) disease (OR 1.748, 95% CI 1.160–2.632) and lymph node metastasis (OR 1.963, 95% CI 1.207–3.194). The pattern was consistent with the other three NUCB2 SNPs studied, all showing associations with progression rather than susceptibility — supporting the hypothesis that reduced nesfatin-1 activity impairs anti-tumor immune surveillance or directly promotes tumor invasiveness in older patients.

Nesfatin-1 and cancer biology. A 2021 review by Kmiecik et al.⁴⁴ Kmiecik et al.
Kmiecik AM et al. Nucleobindin-2/Nesfatin-1-A New Cancer Related Molecule? Int J Mol Sci, 2021 synthesized evidence that nesfatin-1 exhibits anti-proliferative and pro-apoptotic effects in colorectal, hepatocellular, and other cancer cell lines. Reduced serum nesfatin-1 has been documented in multiple cancer contexts, suggesting a tumor-suppressive function that nesfatin-1 deficiency (from either obesity or genetic factors reducing NUCB2 expression) may undermine.

Sleep biology. rs10766383 has not been studied directly in sleep research, but NUCB2/nesfatin-1 has an established role in sleep-wake regulation. Vas et al. (2013, PLoS One)⁵⁵ Vas et al. (2013, PLoS One)
Vas S et al. Nesfatin-1/NUCB2 as a potential new element of sleep regulation in rats. PLoS One, 2013 showed that central nesfatin-1 reduces REM sleep and increases wakefulness in rats, and that hypothalamic NUCB2 expression rebounds during sleep recovery after deprivation. Intronic variants reducing NUCB2 output may therefore affect sleep architecture at the population level, though direct human data at rs10766383 are lacking.

Practical Implications

The T2DM association is female-specific and of moderate effect size (OR ~1.3). The most actionable implication is metabolic monitoring in female T carriers — fasting glucose and insulin resistance markers are the appropriate early warning signals. For the oral cancer finding, the association applies to older patients already diagnosed (progression risk), not susceptibility, so oncological surveillance context is the practical frame for GT/TT carriers, particularly males over 60.

Interactions

rs10766383 was studied alongside rs1330, rs214101, and rs757081 in both the Li 2020 T2DM and Yu 2026 oral cancer papers. All four NUCB2 variants showed broadly consistent directions of effect — T2DM risk (Li 2020) and oral cancer progression risk (Yu 2026) — suggesting they may act as a haplotype or collectively reduce NUCB2/nesfatin-1 output through complementary regulatory and protein-level mechanisms. Individuals carrying risk alleles at multiple NUCB2 loci may experience compounded nesfatin-1 insufficiency beyond what any single variant predicts.

Most people who know about BDNF (brain-derived neurotrophic factor) know it as the brain's plasticity hormone — the factor that strengthens memories, supports neuroplasticity, and responds to exercise. That well-known story belongs to rs6265 (Val66Met), a coding variant that affects BDNF secretion in neurons and is covered in the Brain & Mental Health section of this encyclopedia.

This variant — rs10767664 — tells a different story entirely. It sits in intron 3 of the BDNF gene, within a conserved enhancer region called BE5.1¹¹ conserved enhancer region called BE5.1
A 494 base pair stretch of DNA that has been preserved across vertebrate evolution for over 360 million years, suggesting a critical biological function. It controls BDNF expression specifically in hypothalamic cells, and it affects BDNF's role not in learning and memory but in hypothalamic satiety signaling²² hypothalamic satiety signaling
The process by which the hypothalamus receives signals from the body that food intake is sufficient and suppresses appetite. BDNF in the ventromedial hypothalamus is a critical relay in this satiety circuit. This variant was identified in one of the largest genome-wide association studies of body mass index ever conducted, affecting approximately 250,000 individuals, and the association is among the strongest ever found for obesity.

The Mechanism

BDNF is highly expressed in the ventromedial hypothalamus (VMH)³³ ventromedial hypothalamus (VMH)
The region of the hypothalamus primarily responsible for satiety. Neurons here receive leptin signals and fire to suppress appetite. When BDNF signaling in the VMH is reduced, animals overeat and gain weight, where it functions as a critical downstream effector of the melanocortin-4 receptor (MC4R) pathway⁴⁴ melanocortin-4 receptor (MC4R) pathway
MC4R is activated by alpha-MSH, a hormone produced when leptin signals "enough food." MC4R activation upregulates BDNF in the VMH, which then sustains the satiety signal. This is why MC4R and BDNF variants both appear as top obesity GWAS hits — they are in the same molecular pathway. When you eat and leptin rises, MC4R activation stimulates BDNF expression in VMH neurons⁵⁵ stimulates BDNF expression in VMH neurons
Xu B et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nature Neuroscience, 2003, and that BDNF signal then propagates satiety through TrkB receptors, suppressing further food intake.

The rs10767664 A allele disrupts this process at the source. Research in primary hypothalamic cells shows that the T allele (the protective minor allele) functions as an active enhancer of BDNF promoter 4 — driving BDNF transcription in response to neuronal signals. The A allele, which is actually the more common version, fails to enhance promoter activity. The result: reduced BDNF expression in the hypothalamus, weaker satiety signaling after meals, and a sustained drive to keep eating.

Recent research further refined this picture by showing that astrocytes in the VMH⁶⁶ astrocytes in the VMH
Non-neuronal support cells that regulate synaptic communication. VMH astrocytes express TrkB.T1 (a truncated BDNF receptor) and use BDNF signaling to modulate neuronal activity in response to energy state also require intact BDNF/TrkB signaling⁷⁷ require intact BDNF/TrkB signaling
Ameroso et al. Astrocytic BDNF signaling within the ventromedial hypothalamus regulates energy homeostasis. Nature Metabolism, 2022 for normal energy homeostasis. Mice lacking TrkB.T1 in VMH astrocytes develop increased body weight, leptin resistance, and impaired glucose tolerance — a metabolic syndrome profile strikingly similar to what rs10767664 A homozygotes are at risk for.

The Evidence

The GIANT consortium meta-analysis⁸⁸ GIANT consortium meta-analysis
Speliotes EK et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010 of 249,796 individuals identified the BDNF locus as one of 18 new BMI- associated signals, with rs10767664 reaching p = 5 × 10⁻²⁶ — far beyond the genome-wide significance threshold. Each copy of the A allele increases BMI by an estimated 0.19 kg/m² (95% CI 0.13–0.25), placing the BDNF locus among the strongest obesity GWAS hits identified. The effect was confirmed in a diverse-ancestry replication cohort.

Human feeding data confirms the mechanistic prediction. In the Look AHEAD Trial⁹⁹ Look AHEAD Trial
A large NIH-funded trial studying lifestyle intervention for overweight adults with type 2 diabetes, n=5,145, carriers of the AA genotype consumed over 100 kcal per day more¹⁰¹⁰ carriers of the AA genotype consumed over 100 kcal per day more
McCaffery et al. Obesity susceptibility loci and dietary intake in the Look AHEAD Trial. Am J Clin Nutr, 2012 than carriers of the T allele (p = 0.006), and this effect persisted after adjusting for body weight — confirming it reflects an appetite difference, not just a consequence of greater body mass.

The metabolic consequences extend beyond weight. In a prospective study of 507 obese Caucasian women, T allele carriers faced 1.33-fold higher odds of type 2 diabetes¹¹¹¹ T allele carriers faced 1.33-fold higher odds of type 2 diabetes
de Luis DA et al. rs10767664 gene variant in BDNF is associated with diabetes mellitus type 2 in Caucasian females with obesity. Ann Nutr Metab, 2017 (95% CI 1.17–2.08) compared to non-carriers, with higher BMI, waist circumference, fasting glucose, HOMA-IR, insulin, and CRP in the T-carrier diabetic subgroup. A separate intervention study in 80 obese patients on a calorie-restricted diet found AA homozygotes lost significantly more weight¹²¹² AA homozygotes lost significantly more weight
de Luis DA et al. RS 10767664 gene variant in brain derived neurotrophic factor (BDNF) affect metabolic changes and insulin resistance after a standard hypocaloric diet. J Diabetes Complications, 2018 (3.4 vs 1.7 kg, p=0.01) with better fat mass reduction, triglyceride improvement, and insulin sensitivity gains than T carriers, suggesting T allele carriers may have a complex metabolic phenotype with worse insulin resistance independent of current weight.

Practical Implications

The A risk allele is very common — roughly 63% of people of European descent are AA homozygotes and another 32% are AT heterozygotes. Carrying the risk allele does not mean inevitable obesity; it means your hypothalamic satiety brake at this locus is less powerful than in the uncommon TT genotype. The 100 kcal/day difference in intake observed in the Look AHEAD trial is modest in isolation, but accumulated over months and years — and compounded with other obesity-risk loci — it represents a genuine appetite disadvantage worth counteracting proactively.

The most genotype-specific intervention follows directly from the mechanism: strategies that enhance post-meal satiety signaling (protein-first eating, high-fiber meal starters, time-structured eating) can compensate for reduced hypothalamic BDNF tone. For AA and AT carriers with metabolic concerns, monitoring fasting insulin and HOMA-IR provides an early warning signal for insulin resistance that this genotype predisposes to.

Interactions

rs10767664 and MC4R (rs17782313) are in the same satiety signaling cascade. BDNF is a downstream effector of MC4R in the VMH, meaning both proteins must function for full satiety signal propagation. A carrier of both the MC4R risk allele (rs17782313 C) and the BDNF obesity allele (rs10767664 A) has impairment at two consecutive steps in the same hypothalamic circuit, creating a compounded appetite dysregulation greater than either variant alone. Specific interaction studies at the genotype level have not been published, but the shared mechanistic pathway provides a strong biological rationale.

FTO (rs9939609) and rs10767664 operate through independent mechanisms — FTO primarily affects thermogenesis and adipogenesis through IRX3/IRX5 in brown fat and hypothalamus, while rs10767664 acts on VMH satiety signaling via the BDNF-TrkB pathway. Their BMI effects are additive rather than synergistic. Large-scale polygenic risk score analyses confirm that carrying risk alleles at both loci produces meaningfully higher obesity risk than either alone.

This variant is distinct from rs6265 (BDNF Val66Met), which is catalogued in the Brain & Mental Health section. rs6265 is a missense variant in the BDNF coding sequence that impairs activity-dependent BDNF secretion from neurons, affecting memory and neuroplasticity. rs10767664 is a regulatory variant that reduces BDNF expression in the hypothalamus, affecting satiety signaling and energy balance. The two variants show weak linkage disequilibrium and can be inherited independently — a person may carry one, both, or neither risk allele.

Your immune system uses antibodies as molecular flags — tagging pathogens and cellular debris for removal. The actual removal work is done by macrophages, neutrophils, and dendritic cells carrying a surface receptor called FcγRIIa, encoded by FCGR2A. This receptor is the cell's sensor for IgG antibody complexes: when an immune complex¹¹ immune complex
A cluster of antigens bound by multiple IgG antibodies, forming a molecular aggregate that signals phagocytes to engulf and destroy the target lands on a macrophage's FcγRIIa receptor, the cell ingests and destroys it. rs10800309 sits in a regulatory region of FCGR2A that controls how many of these receptors appear on the cell surface — influencing the immune system's overall capacity to clear immune complexes before they accumulate in tissues and trigger inflammation.

When immune complex clearance is impaired — whether through reduced receptor affinity (the well-studied rs1801274 H131R variant) or through reduced receptor quantity (the mechanism implicated by rs10800309) — immune complexes can deposit in the kidneys, joints, and small vessels, triggering the complement cascade and the chronic inflammation that characterizes diseases like lupus nephritis and rheumatoid arthritis.

The Mechanism

rs10800309 is located approximately 3.1 kilobases upstream of the FCGR2A transcription start site, within a region identified by CRISPR-based regulatory mapping²² CRISPR-based regulatory mapping
Researchers used CRISPR interference (CRISPRi) to systematically silence 1.7 Mb of open chromatin around FCGR2A, identifying upstream subregions that reduce transcript levels when silenced as harboring important enhancer activity for FCGR2A expression in myeloid cells. It forms a tight [haplotype block | A haplotype block is a chromosomal region where alleles co-segregate due to limited historical recombination; variants in the same block often tag the same underlying functional change] with rs4657039 and rs6696854, suggesting that all three variants together mark the same functional change in the upstream regulatory region.

The A allele at rs10800309 is associated with higher FcγRIIa surface expression on myeloid cells including dendritic cells and monocytes. Carriers of the AA genotype show statistically increased receptor density, while GG homozygotes show the lowest expression. This is consistent with the variant acting as an expression quantitative trait locus (eQTL)³³ expression quantitative trait locus (eQTL)
An eQTL is a DNA variant that predicts how much of a gene product is made — not what the protein looks like, but how many copies are produced for FCGR2A in immune cells. The downstream consequence is quantitative: fewer receptors means slower, less efficient capture and clearance of IgG immune complexes.

The Evidence

The most direct evidence for rs10800309's functional importance comes from a cohort study of HIV controllers⁴⁴ cohort study of HIV controllers
251 HIV controllers vs 250 HIV progressors from predominantly Caucasian cohorts; controller status defined as viral load below 400 copies/mL without antiretroviral therapy (Roederer et al., Genes & Immunity, 2020) that genotyped five FCGR2A SNPs in 501 participants. The AA genotype of rs10800309 was associated with natural HIV-1 control with an odds ratio of 2.84 (95% CI 1.20–6.89, P=0.033) even after adjusting for HLA-B57 and HLA-B27 — the dominant genetic determinants of HIV control. Crucially, the same AA genotype was independently confirmed to predict increased FcγRIIa surface expression on myeloid dendritic cells in a flow cytometry experiment (P=0.0032), establishing that the genotype operates through receptor quantity, not receptor structure.

In the context of autoimmune disease, rs10800309 was investigated as part of a five-SNP FCGR2A haplotype study⁵⁵ five-SNP FCGR2A haplotype study
422 UC patients and 710 healthy controls from southeastern China; haplotype analysis using PHASE software in ulcerative colitis. While the individual genotype frequencies of rs10800309 did not reach significance between patients and controls, the haplotype block it anchors (rs4657039-rs6696854-rs10800309) is an independently inherited segment that collectively influences FCGR2A expression. Separately, the FCGR2A locus — including the broader region containing this haplotype block — has been replicated as an ulcerative colitis susceptibility locus⁶⁶ ulcerative colitis susceptibility locus
GWAS-identified locus with genome-wide significant p-values in Japanese and Korean IBD cohorts.

The biological mechanism linking reduced FcγRIIa expression to autoimmunity is well-established through work on the companion missense variant rs1801274. Individuals with lower-functioning FcγRIIa fail to efficiently clear IgG-opsonized immune complexes; these complexes accumulate in tissues, activate complement, and drive the chronic inflammation underlying lupus nephritis, rheumatoid arthritis, and inflammatory bowel disease. The rs10800309 expression-level effect operates in parallel to this receptor-function effect — compounding risk when the G allele co-occurs with the R131 (G allele of rs1801274) functional variant.

Practical Actions

The GG genotype at rs10800309 reflects reduced FcγRIIa receptor quantity on myeloid cells. For most people, this is a background predisposition rather than a deterministic disease signal — particularly if the companion rs1801274 genotype indicates adequate receptor affinity. The most evidence-backed strategies target the downstream consequences of suboptimal immune complex clearance: supporting immune resolution through long-chain omega-3 fatty acids and vitamin D, and monitoring for early signs of immune complex deposition in susceptible individuals with family history.

Omega-3 fatty acids (EPA and DHA) promote the production of specialized pro-resolving mediators (SPMs)⁷⁷ specialized pro-resolving mediators (SPMs)
Lipid compounds derived from EPA and DHA that actively terminate inflammatory responses by promoting clearance of cellular debris and inhibiting pro-inflammatory cytokine production, compensating downstream for upstream impairments in receptor-mediated immune complex clearance.

Interactions

rs10800309 belongs to the second haplotype block of FCGR2A (block 1: rs4657039, rs6696854, rs10800309) distinct from the block containing rs1801274 (the well-studied H131R missense variant). The two blocks are independently inherited, meaning a person can carry the expression-reducing G allele at rs10800309 AND the affinity-reducing R131 allele at rs1801274 simultaneously — a combination that impairs both receptor quantity and receptor function simultaneously. This dual impairment creates the most pronounced deficit in immune complex clearance and may represent the highest-risk combination in the FCGR2A locus.

rs396991 (FCGR3A, F158V) encodes a separate but related Fc receptor expressed on NK cells and macrophages. Compound carriage of reduced-expression rs10800309 G alleles with reduced-function FCGR3A F158 alleles broadly depresses Fc-receptor-mediated immune surveillance across multiple cell lineages — an interaction relevant to both autoimmune clearance and antibody-dependent cellular responses to infections and biologics.

Every egg maturation cycle and every sperm development program depends on a precise dose of follicle-stimulating hormone (FSH). FSH is a two-subunit hormone: the alpha subunit is shared with LH, TSH, and hCG, but the beta subunit (FSHB)¹¹ beta subunit (FSHB)
The beta subunit determines FSH's receptor-binding specificity — it is the component that targets FSH exclusively to ovarian granulosa cells and testicular Sertoli cells is unique to FSH and sets its production rate. The c.-211G>T variant sits in the FSHB promoter, 211 base pairs upstream of the transcription start site, and quietly reduces how much of this hormone the pituitary can make — with consequences that play out across a person's entire reproductive life.

The Mechanism

The G-to-T substitution at position -211 falls within a conserved binding site for LHX3²² LHX3
LIM homeobox transcription factor 3, expressed in pituitary gonadotroph cells; essential for FSH but not LH production, a homeodomain protein that drives basal FSHB expression in pituitary gonadotroph cells. Functional studies show that LHX3 binds with measurably lower affinity to the T-allele promoter, and when the T allele is tested in luciferase reporter assays, the promoter produces only 46–58% of the transcriptional output of the G allele³³ only 46–58% of the transcriptional output of the G allele
Measured in LβT2 gonadotroph cells using matched promoter constructs; reproduced independently by two research groups.

This reduced promoter activity translates directly into lower circulating FSH. The effect is additive: heterozygotes (GT) have roughly 13–16% less FSH than GG individuals, and TT homozygotes have approximately 40–50% less FSH⁴⁴ TT homozygotes have approximately 40–50% less FSH
Both figures replicated in independent Baltic, Estonian, and German cohorts; the Estonian study used n=554 healthy men. Because FSH drives Sertoli cell proliferation during fetal and neonatal development — a window that determines permanent testicular size and spermatogenic capacity — the effect on males extends well beyond adult hormone levels.

The Evidence

In males, the consequences of lifelong reduced FSH are measurable at the organ level. A large Baltic cohort study⁵⁵ A large Baltic cohort study
Grigorova et al., Genetically Determined Dosage of Follicle-Stimulating Hormone Affects Male Reproductive Parameters. JCEM, 2011 of 1,054 men showed that TT homozygotes had ~20% smaller testicular volume (38 mL vs 47 mL), 21% lower inhibin-B (a direct Sertoli cell product), and lower testosterone compared to GG carriers. FSH reduction per T allele was 0.51 IU/L in combined meta-analysis. The T allele was enriched among infertile men in multiple cohorts: one study of 1,029 infertile men and 554 fertile controls⁶⁶ one study of 1,029 infertile men and 554 fertile controls
Tüttelmann et al., JCEM, 2012 found TT genotype in 2.4% of infertile vs 1.1% of fertile men. In non-obstructive azoospermia patients undergoing TESE (testicular sperm extraction)⁷⁷ non-obstructive azoospermia patients undergoing TESE (testicular sperm extraction)
Busch et al., JCEM, 2019, the T allele significantly predicted failed sperm retrieval, an association that held even after adjusting for FSH levels — suggesting a direct effect on spermatogenesis beyond the hormonal signal alone.

In females, a large genetic association study using UK Biobank data (up to 63,350 women)⁸⁸ a large genetic association study using UK Biobank data (up to 63,350 women)
Ruth et al., Human Reproduction, 2016 demonstrated that each T allele lengthens the menstrual cycle by approximately 1 day (0.16 SD; P=6×10⁻¹⁶) and delays menopause by 0.13 years, consistent with lower FSH slowing ovarian follicle recruitment and depletion. The same T allele was protective against endometriosis⁹⁹ protective against endometriosis
OR 0.79, 95% CI 0.69–0.90; P=4.1×10⁻⁴; consistent with FSH's role in promoting estrogen production from developing follicles but increased the probability of nulliparity (OR 1.06), suggesting reduced conception efficiency. For women undergoing IVF, a Brazilian study (n=140)¹⁰¹⁰ a Brazilian study (n=140)
Trevisan et al., Genetic Testing and Molecular Biomarkers, 2019 found that GT carriers had significantly fewer antral follicles (8.0 vs 10.0; P=0.03), fewer oocytes retrieved (3.0 vs 5.0; P=0.03), and nearly double the rate of poor response to controlled ovarian stimulation (47.4% vs 26.5%; P=0.010).

Practical Implications

The T allele does not prevent fertility; it reduces FSH-driven amplification of the reproductive signal. For carriers planning assisted reproduction, this has direct protocol implications: lower baseline FSH may indicate a need for adjusted gonadotropin dosing. For male T-allele carriers, the implications are most acute in azoospermia evaluation — when TESE is being considered, the genotype may help predict sperm retrieval probability. The variant is also relevant in interpreting unexpectedly normal or low FSH in the context of reproductive difficulty: a "normal" FSH reading in a TT carrier may represent relative FSH insufficiency for that individual's gonadal needs.

Interactions

rs11031006 (FSHB distal enhancer): This batch includes both the proximal promoter variant (c.-211G>T, this SNP) and the distal enhancer SNP rs11031006, located ~26 kb upstream of the FSHB transcription start site. The two SNPs are in moderate linkage disequilibrium (r2 ~0.2–0.3 in Europeans) but have independent functional mechanisms: c.-211G>T impairs LHX3 binding at the proximal promoter, while rs11031006 affects SF1 binding at the distal enhancer. Both reduce FSH transcription via different regulatory inputs, and individuals carrying T alleles at both positions may experience a compounded reduction in FSH output that is not captured by either SNP alone. Direct compound analysis across both variants has not been published, but the additive pathway biology is well-established.

FSHR rs6166 (N680S) + FSHB rs10835638: When FSH production is already reduced (FSHB T allele) and the FSH receptor also operates at lower efficiency (FSHR rs6166 GG/Ser680Ser), the combined effect represents a dual impairment of the FSH axis — reduced signal and reduced receptor sensitivity. A published compound analysis of FSHB c.-211G>T and FSHR 2039A>G (rs6166) in 3,017 men confirmed that the FSHR variant significantly modulated the already-dominant FSHB T-allele effect on FSH and testicular volume. For IVF protocols, this dual-impairment signature may predict a lower-than-expected response to standard FSH stimulation doses and would warrant earlier dose escalation review. Proposed compound action: rs10835638 (GT or TT) + rs6166 (GG) — "Dual FSH Axis Impairment: Low Production and Reduced Receptor Sensitivity." Action type: monitoring + lifestyle (IVF protocol disclosure). Evidence level: moderate.

IRF1/RAD50 rs13164856 + FSHB rs10835638: rs13164856 is a PCOS-susceptibility tag SNP at 5q31 specifically associated with testosterone levels. Women carrying the rs13164856 T allele (androgen-excess) alongside the FSHB T allele (low FSH) may face compound reproductive challenges: elevated androgens combined with reduced FSH-driven follicle development. This represents two distinct PCOS pathways converging — androgen excess and gonadotropin insufficiency.

Inside every vascular smooth muscle cell, a molecular tug-of-war determines whether your blood vessels relax or contract. On one side: cyclic AMP (cAMP), a signalling molecule that promotes vasodilation. On the other: phosphodiesterase 3A (PDE3A)¹¹ phosphodiesterase 3A (PDE3A)
the enzyme that degrades cAMP and terminates its vasodilatory signal. The balance between cAMP production and degradation governs vascular tone, cardiac contractility, and platelet activation. The rs10841496 variant sits in the 5' untranslated region (5' UTR) of the PDE3A gene — a regulatory zone that influences how much protein the gene produces.

PDE3A gained clinical prominence when rare gain-of-function mutations in its coding sequence were found to cause an autosomal dominant syndrome of severe salt-independent hypertension with brachydactyly type E²² severe salt-independent hypertension with brachydactyly type E
shortened fingers and toes co-occur with dangerous blood pressure elevations in every affected family member. This rare syndrome crystallised the mechanism: when PDE3A is overactive, cAMP degrades too fast, vascular smooth muscle cells proliferate and cannot relax normally, and blood pressure climbs. The rs10841496 variant, by contrast, is common and operates at a regulatory level — potentially nudging PDE3A expression rather than altering the enzyme itself.

The Mechanism

The 5' UTR of a gene is not translated into protein but powerfully shapes how much protein gets made. 5' UTR sequences contain secondary structures, upstream open reading frames, and binding sites for RNA-binding proteins³³ 5' UTR sequences contain secondary structures, upstream open reading frames, and binding sites for RNA-binding proteins
these elements control ribosome loading and mRNA stability, affecting protein output without changing amino acid sequence. A variant here can increase or decrease steady-state PDE3A protein levels in vascular smooth muscle cells, cardiac myocytes, and platelets — the three tissues where PDE3A is most highly expressed.

PDE3A degrades both cAMP and cGMP. Elevated PDE3A activity blunts both the beta-adrenergic (cAMP) and nitric oxide (cGMP) vasodilatory pathways simultaneously. PDE3A-knockout mouse studies⁴⁴ PDE3A-knockout mouse studies
mice lacking PDE3A show reduced vascular smooth muscle cell proliferation and impaired mitogen-driven growth confirm that normal PDE3A activity is necessary for VSMC cell cycle progression — an activity that becomes pathological when the enzyme is overexpressed or hyperactive.

In platelets, PDE3A is the principal enzyme controlling intracellular cAMP. Cilostazol, a selective PDE3A inhibitor used clinically for peripheral arterial disease⁵⁵ Cilostazol, a selective PDE3A inhibitor used clinically for peripheral arterial disease
elevates platelet cAMP, suppressing aggregation and reducing pro-thrombotic extracellular vesicle release. Higher endogenous PDE3A expression could thus counteract this platelet-quiescent cAMP pool, tipping the balance toward greater platelet activation.

The Evidence

The strongest evidence linking this locus to blood pressure comes from population genetics. The 2015 trans-ancestry GWAS by Kato et al.⁶⁶ The 2015 trans-ancestry GWAS by Kato et al.
75,000+ participants of Asian, European, and African ancestry identified PDE3A as a methylation-enriched blood pressure locus — a finding replicated in a 2022 Chinese cohort study of 1,241 participants using Mendelian randomization, which confirmed that DNA methylation at PDE3A promoter CpG sites is causally associated with blood pressure variation ⁷⁷ PMID 35087571.

At the pharmacogenomics level, Iniesta et al. (2019)⁸⁸ Iniesta et al. (2019)
4,696 participants across five antihypertensive drug trials found that PDE3A locus variants explained differences of −3.5 to +3.5 mmHg per allele in blood pressure response to candesartan (ARB) and hydrochlorothiazide (thiazide), with differential effects between Black and White participants. This suggests the PDE3A locus influences not just baseline blood pressure but also the pharmacological response to antihypertensive medication.

The specific functional consequence of rs10841496 — a C>A transversion in the 5' UTR — remains incompletely characterised at the molecular level. No published study has directly measured PDE3A expression as a function of this genotype. The evidence for blood pressure effects is therefore indirect, resting on locus-level GWAS associations rather than variant-resolved mechanistic data. This places the evidence at the emerging level for this specific SNP.

One additional signal: rs10841496 was identified among variants significantly associated with semen quality parameters in a Han Chinese case-control study ⁹⁹ 136 subfertile men versus 456 fertile controls, consistent with PDE3A's known role in regulating sperm motility through cAMP signalling in flagellar dynein.

Practical Actions

Carriers of the AA genotype may experience modestly altered PDE3A expression, with downstream effects on vascular tone and platelet reactivity. Given the locus-level evidence for blood pressure effects, cardiovascular monitoring is the most evidence- grounded action. If blood pressure is borderline or elevated, the PDE3A locus evidence suggests cilostazol (a PDE3A inhibitor) or antihypertensive agents targeting the renin-angiotensin-aldosterone system may be particularly relevant — though the pharmacogenomic data are insufficient to override standard prescribing guidelines.

Maintaining healthy nitric oxide (NO) signalling — which activates cGMP — can partially compensate for elevated PDE3A activity. Dietary nitrates from vegetables such as beetroot, rocket, and spinach raise plasma nitrite and enhance NO bioavailability through the nitrate-nitrite-NO pathway, bypassing dependence on eNOS enzymatic activity.

Interactions

PDE3A shares the cyclic nucleotide degradation network with PDE3B (expressed in adipose and liver), PDE4 isoforms (dominant in many immune and vascular cells), and PDE5 (the cGMP-specific enzyme). Variants in NOS3 (rs1799983, eNOS Glu298Asp) reduce nitric oxide synthesis — the primary driver of cGMP — and would compound any PDE3A-mediated acceleration of cGMP degradation. Carrying both a reduced-NOS3 and elevated-PDE3A genotype could meaningfully amplify vasoconstrictive tone.

The GWAS locus at 12p12.2 where PDE3A sits spans several nearby genes; the full causal variant(s) in this region have not been resolved to single-SNP resolution. Future fine-mapping studies may clarify whether rs10841496 is a causal regulatory variant or a tag for the true functional allele.

Endometriosis — in which tissue resembling the uterine lining implants and grows outside the uterus — affects approximately 10% of women of reproductive age and accounts for a disproportionate burden of pelvic pain, dyspareunia, infertility, and diagnostic delay. The condition is strongly heritable; genetic factors explain roughly 50% of susceptibility variance. rs10859871, an intronic variant near the VEZT gene at chromosome 12q22, is one of the most robustly replicated genome-wide association signals for endometriosis, confirmed across multiple independent datasets in European and Japanese populations.

VEZT encodes vezatin¹¹ vezatin
a ubiquitous transmembrane protein of adherens junctions — the intercellular adhesion structures that link neighboring epithelial and endothelial cells via the cadherin–catenin–actin axis. Vezatin is a 779 amino acid protein embedded in the transmembrane domain of adherens junctions; it interacts with myosin VIIa and the cadherin–catenin complex to stabilize cell-cell contacts and regulate cytoskeletal tension. Disruption of adherens junction integrity is a recognized feature of endometriotic stromal cells, enabling the detachment, peritoneal transit, and ectopic re-implantation that characterize endometriosis.

The Mechanism

rs10859871 sits in an intron of VEZT and does not alter the vezatin protein sequence. Its clinical relevance lies in its function as a cis-eQTL²² cis-eQTL
an expression quantitative trait locus — a genetic variant that regulates the expression level of a nearby gene in cis, meaning on the same chromosome. The endometriosis risk allele (C) is associated with increased VEZT mRNA levels in both blood and endometrial tissue, as demonstrated by Holdsworth-Carson et al. using samples from 228 women across four endometrial compartments. This upregulation suggests that the C allele alters transcription factor binding or chromatin accessibility at the intronic locus, shifting vezatin expression toward levels that may paradoxically destabilize adherens junction dynamics rather than reinforce them — possibly through titrating junction components or activating feedback suppression.

In endometriotic stromal cells, adherens junction weakening reduces E-cadherin-mediated cohesion, facilitating epithelial–mesenchymal transition and invasive behavior analogous to metastatic cancer cells. Vezatin's role in connecting myosin VIIa to the cadherin complex places it at the intersection of mechanosensing and junction stability: altered vezatin levels could shift the balance between adhesion and contractility-driven detachment in endometrial cells shed during retrograde menstruation. Protein-level confirmation of the eQTL effect in endometrial tissue has not yet been published, and functional studies directly testing vezatin's causal role in endometriosis pathogenesis remain warranted.

The Evidence

The initial genome-wide significant association was reported by Nyholt et al. in Nature Genetics (2012)³³ Nyholt et al. in Nature Genetics (2012)
GWAS meta-analysis of 4,604 cases and 9,393 controls from Japanese and European cohorts identified seven endometriosis loci; rs10859871 at 12q22/VEZT reached P = 5 × 10⁻¹³, OR ~1.2 (95% CI 1.14–1.26). The signal was independent of the other known endometriosis loci and consistent across both ancestral groups studied.

A subsequent replication and meta-analysis by Pagliardini et al. (Human Reproduction, 2015)⁴⁴ replication and meta-analysis by Pagliardini et al. (Human Reproduction, 2015)
confirmed rs10859871 as the locus with the single strongest statistical support for endometriosis association; OR = 1.19, P = 7.9 × 10⁻²⁰ across combined datasets. Effect sizes were stronger in Stage III/IV disease than in milder stages, suggesting this locus is particularly implicated in moderate-to-severe and ovarian disease.

The Rahmioglu et al. meta-analysis (Human Reproduction Update, 2014)⁵⁵ Rahmioglu et al. meta-analysis (Human Reproduction Update, 2014)
11,506 cases and 32,678 controls across eight GWAS datasets; rs10859871 genome-wide significant at P = 4.7 × 10⁻¹⁵; all nine replicated loci showed stronger effects in Stage III/IV reached the same conclusion. The C allele's effect is consistent across European and East Asian populations, adding cross-ancestry evidence to the association.

A systematic review of endometriosis GWAS studies (Cardoso et al., 2020)⁶⁶ systematic review of endometriosis GWAS studies (Cardoso et al., 2020)
15 studies reviewed; VEZT rs10859871 was one of five variants highlighted as having the highest frequency of replication across independent datasets ranked rs10859871 among the five most consistently replicated endometriosis genetic signals alongside WNT4, GREB1, FN1, and IL1A loci.

Practical Implications

Carrying the C allele at rs10859871 confers a modest but well-established increase in endometriosis susceptibility, with an odds ratio of approximately 1.19 per C allele. The absolute risk contribution of a single locus is modest relative to the condition's overall ~10% population prevalence, but this signal combines additively with risk alleles at other confirmed loci (WNT4, GREB1, FN1, CDKN2B-AS1, IL1A, and HOXA10/11 loci).

The clearest clinical implication is awareness: the diagnostic delay for endometriosis averages 4–11 years from symptom onset, and genetic risk signals support a lower threshold for specialist evaluation when relevant symptoms are present. C allele carriers with symptoms consistent with endometriosis benefit from proactive gynecological referral rather than normalization of pelvic pain.

Interactions

rs7521902 (WNT4 locus, 1p36.12): WNT4 regulates Müllerian duct development and ovarian sex-steroid production. WNT4 and VEZT risk alleles are among the most replicated endometriosis loci; additive polygenic burden across these loci is expected under the established polygenic architecture, though formal interaction testing between rs10859871 and rs7521902 has not been published.

rs13394619 (GREB1, 2p25.1): GREB1 is an estrogen-responsive gene involved in endometrial proliferation. The combination of GREB1 and VEZT risk alleles likely contributes additively to endometriosis susceptibility through distinct pathways (hormonal regulation vs. adhesion junction mechanics).

rs1537377 (CDKN2B-AS1/ANRIL, 9p21.3): This locus near the cell-cycle regulatory genes CDKN2A/CDKN2B on chromosome 9 is a separate endometriosis GWAS signal. The CDKN2B-AS1 locus and the VEZT locus represent distinct genetic contributions to endometriosis risk — both have been confirmed in the same multi-locus meta-analyses.

rs1250248 (FN1, 2q34): The fibronectin gene is a confirmed endometriosis locus with particularly strong effects in Stage III/IV disease. Fibronectin-mediated ECM remodeling and vezatin-mediated adherens junction regulation both affect how ectopic endometrial cells adhere, invade, and persist — pathway-level convergence between these two loci is plausible.

At the heart of the innate immune system sits a protein called IRF5 (Interferon Regulatory Factor 5)¹¹ IRF5 (Interferon Regulatory Factor 5)
A master transcription factor that, when activated by viral or microbial signals, enters the cell nucleus and switches on genes for type I interferons and pro-inflammatory cytokines including TNF-α, IL-6, and IL-12. IRF5 is the key decision-maker that determines how vigorously your immune system responds to threats — but when it runs too high chronically, it becomes a driver of autoimmune disease. The rs10954213 variant, located in the 3' untranslated region of the IRF5 gene, is the best-characterized causal variant in one of genetics' most replicated autoimmune susceptibility loci. Unlike the nearby rs2004640 variant (which alters mRNA splicing) and rs2280714 (which is a tag SNP in linkage disequilibrium), rs10954213 directly controls how long the IRF5 messenger RNA survives in the cell — and therefore how much IRF5 protein gets made.

The Mechanism

The rs10954213 variant works through a process called alternative polyadenylation²² alternative polyadenylation
A mechanism by which the same gene can produce mRNA molecules of different lengths from the same 3' end; the cell's RNA-processing machinery recognizes a signal sequence (AAUAAA) and cleaves the mRNA at that point, adding a poly-A tail that protects the mRNA from degradation. The A allele of rs10954213 creates a canonical AAUAAA polyadenylation signal approximately 100 nucleotides upstream of the default cleavage site. When this proximal signal is present, the cell's polyadenylation machinery cleaves the mRNA at that upstream position, producing a shorter 3'-UTR isoform. This shorter transcript has two important properties: it escapes microRNA-mediated degradation³³ microRNA-mediated degradation
MicroRNAs are small RNA molecules that bind to complementary sequences in the 3'-UTR and mark mRNA transcripts for degradation; the longer 3'-UTR contains more such binding sites, making the longer isoform less stable that would normally limit IRF5 protein levels, and it accumulates in the cytoplasm at higher concentrations.

The G allele disrupts this proximal polyadenylation signal, forcing the cell to use a more distal cleavage site. The resulting longer 3'-UTR is less stable and contains more miRNA target sites, leading to lower IRF5 protein output. The UK SLE families study⁴⁴ UK SLE families study
Cunninghame Graham et al., Human Molecular Genetics 2007; 380 SLE nuclear families from the United Kingdom identified rs10954213 as the functional element with the strongest correlation to IRF5 mRNA expression levels (P=1×10⁻¹⁴). Consistent with its role as a proximate causal variant, rs10954213-A is in tight linkage disequilibrium with rs2280714-T (r²=0.79, D'=1.0), meaning that population studies using rs2280714 as a tag SNP are effectively measuring the same functional signal.

The Evidence

The most direct functional evidence comes from lymphoblastoid cell line studies across three ancestral populations. The Rullo et al. study⁵⁵ Rullo et al. study
Ann Rheum Dis 2010; lymphoblastoid cells from CEU (European), CHB+JPT (East Asian), and YRI (Yoruba Nigerian) populations from the HapMap project showed that IRF5 mRNA levels were consistently elevated in A-allele carriers compared to G/G homozygotes, with approximately 1.7-fold higher expression in Europeans — a pattern that held across all three ancestral groups tested. Critically, this elevated mRNA translated to elevated production of type I interferons (IFN-α) and IFN-inducible chemokines, directly linking the mRNA stability effect to downstream immune output.

For systemic lupus erythematosus (SLE), the rs10954213-A allele is part of the TAT risk haplotype (rs2004640-T / rs10954213-A / rs2280714-T) that has been replicated across more than 28 studies. A meta-analysis of these studies⁶⁶ meta-analysis of these studies
Systemic review: 11,228 SLE cases and 14,374 controls; Bentham et al. Nature Genetics 2019 found overall OR=1.39 for the T allele at rs2004640 (the haplotype tag), with the combined haplotype signal reaching P=2.11×10⁻¹⁶ when the Korean replication data are pooled across ancestries. The A allele's contribution is functional: Niewold et al.⁷⁷ Niewold et al.
Ann Rheum Dis 2012; 200+ SLE patients and controls showed that IRF5 haplotypes carrying rs10954213-A explained over 70% of genetic risk for elevated serum IFN-α, and were specifically linked to production of anti-dsDNA and anti-Ro autoantibodies — the hallmark autoantibodies that drive kidney and skin disease in lupus.

Beyond SLE, the rs10954213-A haplotype is associated with systemic sclerosis (scleroderma). A Japanese cohort study⁸⁸ Japanese cohort study
Furukawa et al. 2010; 283 SSc cases, 279 controls found that the IRF5 3' haplotype showed an OR of 1.42 (95% CI 1.15–1.75, P=0.0012), with preferential enrichment in the most severe disease subtypes — diffuse cutaneous SSc and anti-topoisomerase I antibody-positive disease. This indicates that higher IRF5 expression drives not only susceptibility but also disease severity and phenotype in scleroderma.

Practical Implications

For individuals carrying one or two copies of the A allele, the practical implication is that your innate immune system has a modestly elevated baseline interferon output and a lower threshold for sustaining interferon responses. This does not mean autoimmune disease is inevitable — most A allele carriers remain healthy — but it means earlier recognition and evaluation of symptoms is more important than it would be for GG individuals. The autoimmune conditions most closely linked to this variant are SLE, systemic sclerosis, and Sjögren syndrome. Early diagnosis of these conditions is critical: treatment initiated before significant organ damage dramatically improves long-term outcomes for all three conditions.

For AA homozygotes, the risk picture is more significant. Both chromosomes produce the shorter, high-stability IRF5 mRNA isoform. In the context of concurrent rs2004640-T and rs4728142 indel risk alleles (the full TAT haplotype), the combined effect on IRF5 expression can be substantial, and proactive monitoring with a rheumatologist becomes more medically justified. Serum IFN-α levels in TAT-homozygous SLE patients can be up to 7.6-fold above those seen in protective-genotype individuals, a molecular signature that is measurable and tracked in specialty centers.

Interactions

The rs10954213 variant sits within the broader IRF5 haplotype architecture alongside two other functional elements: rs2004640 (splice site variant enabling alternative exon 1B, increasing IRF5 isoform diversity) and rs4728142 (promoter CGGGG indel that increases SP1 transcription factor binding and IRF5 baseline transcription). Together these three elements drive IRF5 dysregulation at three levels — transcription, splicing, and mRNA stability — and individuals carrying all three risk alleles show the highest IRF5 output and autoimmune risk.

Additionally, IRF5 interacts additively with STAT4 (rs7574865), which sits downstream of IRF5 in the interferon signaling cascade. While IRF5 controls interferon production, STAT4 controls how sensitively immune cells respond to those interferons. Individuals with risk alleles at both loci can reach substantially amplified autoimmune risk — up to OR=6.78 with five combined IRF5+STAT4 risk alleles in Sjögren syndrome — reflecting a feed-forward amplification loop in interferon signaling.